US Patent

US8906890 — Very low-dosed solid oral dosage forms for HRT

Formulation · Assigned to Bayer Intellectual Property GmbH · Expires 2031-10-22 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a solid oral dosage form containing 0.5 mg estradiol and 0.25 mg drospirenone, used for hormone replacement therapy.

USPTO Abstract

The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.

Drugs covered by this patent

Patent Metadata

Patent number
US8906890
Jurisdiction
US
Classification
Formulation
Expires
2031-10-22
Drug substance claim
No
Drug product claim
Yes
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.